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size was 5.8 (+/-1.3) cm. Seventeen patients did not undergo the intervention after initial work-up because of medical co-morbidities (n=12), death before operation (n=2), aneurysm extent (n=2) and preoperative cerebrovascular accident (n=1). The patients were grouped into four disease categories: advanced cerebrovascular disease (symptomatic carotid arterial stenosis, CAS, >60%; asymptomatic CAS >80%); all cerebrovascular disease (any CAS, >60%); advanced lower extremity peripheral vascular occlusive disease (PVOD) (ABI <0.3), and all lower extremity PVOD (ABI <0.6).
Data were not available for 47 patients who were not subjected to the screening protocol. The characteristics of the patients who did and did not undergo the protocol were not statistically different.
Study design
This was a retrospective review of a case series that was carried out in a single centre. The length of and loss to followup were not reported. No blinded assessment method was used.
Analysis of effectiveness
It was not stated whether all the patients included in the initial study sample were accounted for in the effectiveness study. The clinical outcomes used in the analysis were prevalence of NAOD in the four disease categories and the diagnostic value of clinical indications. The patients were classified as having clinical indications for diagnostic screening for occlusive disease on the basis of the documented history or symptoms. Clinical indications of CAS were patients who had had transient ischaemic attacks, amaurosis fugax, a completed stroke, or a history of prior carotid endarterectomy. Clinical indications of PVOD were claudication, rest pain, or a history of amputation.
Effectiveness results
The prevalence of NAOD was: 3.4% in the group of advanced cerebrovascular disease (71% in symptomatic patients), 18% in the group of all cerebrovascular disease (37% in symptomatic patients), 3% in the group of advanced lower extremity PVOD (83% in symptomatic patients), and 12% in the group of all lower extremity PVOD (61% in symptomatic patients).
The sensitivity (sen), specificity (spec), positive predictive value (PPV) and negative predictive value (NPV) of clinical indications were: in the group of advanced cerebrovascular disease, 71% (sen), 85% (spec), 15% (PPV) and 99% (NPV); in the group of all cerebrovascular disease, 37% (sen), 88% (spec), 41% (PPV) and 86% (NPV); in the group of advanced lower extremity PVOD, 83% (sen), 85% (spec), 15% (PPV) and 99% (NPV); and in the group of all lower extremity PVOD, 61% (sen), 88% (spec), 41% (PPV) and 94% (NPV).
Clinical conclusions
The effectiveness analysis showed that the prevalence rate of advanced nonaortic atherosclerotic disease was low and most of the patients with advanced disease presented clinical indications of their disease. This cast doubts on the usefulness of routine preoperative screening for patients with AAA.
Measure of benefits used in the economic analysis
The summary benefit measures were the number of cases identified in the cost-effectiveness analysis and the qualityadjusted life-years (QALYs) in the cost-utility analysis. The numbers of cases identified in all patients, in those who presented clinical indications, and in those who did not present clinical indications, were derived directly from the effectiveness study. The QALYs gained with screening in comparison with medical therapy were derived from another study (see Other Publications of Related Interest), but the methods used to calculate the utility weights were not reported.
Direct costs
Discounting was not relevant since the costs were incurred in less than two years. The unit costs were presented but resource use data were not. The health services in the economic evaluation were carotid duplex examination and lower extremity Doppler scan studies. The cost/resource boundary of the study was that of the third-party payer. The costs were derived from Medicare fee schedules as a proxy for true institutional costs. Information on resource use was based on actual data coming from the sample of patients included in the effectiveness study from January 1995 to October 1998. The price year was not reported. In the cost-utility analysis, only the cost of carotid duplex examination and the incremental cost of carotid endarterectomy when compared with medical management (derived from the literature) were considered.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered.
Currency

US dollars ($).
Sensitivity analysis
Sensitivity analyses were not performed.
Estimated benefits used in the economic analysis
The number of cases identified in each group (expressed as the percentage of cases) was reported (see the 'Effectiveness Results' section). In the cost-utility analysis, 3 cases of advanced CAS were identified in the sample of all patients, versus 2 in the sub-group of patients with clinical manifestations and 1 in the sub-group of those without clinical manifestations. Consequently, the number of QALYs gained (based on an increase of 0.25 QALYs per patient treated) was 0.75 in the sample of all patients, 0.50 in the sub-group of patients with clinical manifestations, and 0.25 in the sub-group of those without clinical manifestations.
